Ruggero Ridolfi

Immunology and Microbiology · Life Sciences

28h-index3.5kcitations161works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(69), Cancer Immunotherapy and Biomarkers(57), CAR-T cell therapy research(39), Cutaneous Melanoma Detection and Management(24), vaccines and immunoinformatics approaches(21)

Publications159 total

Data from A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
2023Open Access
Data from A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
2023Open Access
Supplementary Data from A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
2023Open Access
Supplementary Data from A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
2023Open Access
Biomonitoring of Metals in Children Living in an Urban Area and Close to Waste Incinerators
International Journal of Environmental Research and Public Health·2020· 22 citedOpen Access
[Epidemiological burden and causal factors of childhood cancer: too many uncertainties].
PubMed·2019· 1 cited
Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience
Melanoma Research·2017· 20 cited
The high cancer incidence in young people in Italy: do genetic signatures reveal their environmental causes?
SHILAP Revista de lepidopterología·2016Open Access
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
ESMO Open·2016· 73 citedOpen Access
Circulating microRNAs (miRNAs): Biomarkers for Lung Cancer
Annals of Oncology·2015· 1 citedOpen Access
No city for children
Annals of Oncology·2015Open Access
Cancer Registries Underestimate both the Type of Disease and also Number of Cases due to Pollution
Annals of Oncology·2015
Style modification in breast and Colorectal Cancer Patients: results of a pilot study Long-Survivors
Annals of Oncology·2015Open Access
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
Annals of Oncology·2014· 139 citedOpen Access
Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response
Journal of Translational Medicine·2014· 25 citedOpen Access
AhR (Aryl Hydrocarbon Receptor) Polymorphisms: A Possible Role in TCDD (Dioxins)-AhR Binding and Carcinogenesis
International Journal of Biology·2014· 7 citedOpen Access
Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study
Journal of Translational Medicine·2014· 28 citedOpen Access
Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.
Journal of Clinical Oncology·2014· 3 cited
MicroRNAs and dendritic cell-based vaccination in melanoma patients
Melanoma Research·2014· 12 cited
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
Cancer Investigation·2014· 104 cited
page 1 of 8Next →

Frequent Co-authors

Laura Ridolfi(21), Angela Riccobon(15), Vanna Chiarion‐Sileni(14), Michele Guida(12), Paolo A. Ascierto(11), Massimo Guidoboni(11), Massimiliano Petrini(11), Paola Queirolo(10), Laura Fiammenghi(10), Alessandro Testori(9), Michele Maio(9), Francesco De Rosa(9), Antonella Romanini(8), Anna Maria Granato(8), Emanuela Scarpi(7), Anna Maria Di Giacomo(6), Ester Simeone(6), Elena Pancisi(6), Valentina Ancarani(6), Linda Valmorri(6)